- Hyaluronic Acid
- Polyethylene glycol (PEG)
- Collagen
- Polylactic-co-glycolic Acid
- Others
Autologous Matrix-induced Chondrogenesis Market size was valued at 97.43 million in 2023 and is poised to grow at a CAGR of 8.6% from 2024-2030. Autologous matrix-induced chondrogenesis is a single-step cartilage restoration process that helps to repair the articular cartilage damage. In this process, the microfracture is combined with the bi-layer collagen I/III. Membrane. AMIC is developed for the treatment of osteochondral and traumatic chondral lesions to establish the first-line treatment. The AMIC slows down the cartilage degeneration to delay or avoid partial or total joint replacement surgery.
Global Autologous Matrix Induced Chondrogenesis Market Summary
Study Period
2024-2030Base Year
2023CAGR
8.6%Largest Market
Asia-PacificFastest Growing Market
North-AmericaAutologous Matrix-induced Chondrogenesis Market Dynamics
Increase in the geriatric population more prone for bone and joint disorders is a key factor drives the global autologous matrix-induced chondrogenesis market. Moreover, rise in number of sports injuries, increase in the preference for minimally invasive surgical procedures, less post-operative complications and lower cost compared with conventional surgeries, increasing in the R&D for the advancement in AMIC, rise in disposable income, and increase in the awareness about AMIC in developed and emerging countries are anticipated to surge the global autologous matrix-induced chondrogenesis market over the forecast years. However, lack of favorable reimbursement policies and dearth of skilled professionals and clinical date are restrain the growth of autologous matrix-induced chondrogenesis market over the forecast timeframe.
North-America Got Significant Share
Autologous Matrix-induced Chondrogenesis Market Regional Analysis
Geographically, global autologous matrix-induced chondrogenesis market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America autologous matrix-induced chondrogenesis market is poised to grow due to rise in prevalence of bone and joint disorders, increase in R&D activities by market players, and sophisticated healthcare infrastructure are bolster the market. Europe autologous matrix-induced chondrogenesis market is driving by rise in demand for minimally invasive surgical procedures, presence of skilled professionals in developed countries, and increase in number of sports injuries are surge the market. Asia Pacific autologous matrix-induced chondrogenesis market has prominent share attributed to increase in the medical tourism in Asia Pacific countries, rise in disposable income, and large patient pool in Asia Pacific region are fuel the market.
Latin America
Europe
Asia Pacific
Middle East
North America
Global Autologous Matrix Induced Chondrogenesis Market Segmentation
By Material Type
By Application
- Knee Cartilage Repair
- Elbow Cartilage Repair
- Hip Cartilage Repair
- Others
By End User
- Hospitals
- Clinics
- Ambulatory Surgical Centers (ASCs)
Frequently Asked Questions
The autologous matrix-induced chondrogenesis market size was valued at 97.43 million in 2022
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
The autologous matrix-induced chondrogenesis market key players are Anika Therapeutics, Inc. (U.S.), Arthro-Kinetics AG (Germany), Braun Melsungen AG (Germany), BioTissue AG (Switzerland), CartiHeal (Israel), Geistlich Pharma AG (Switzerland), JRI Orthopaedics Ltd. (AK Medical) (U.K.)
Key Features of the Report
- The autologous matrix-induced chondrogenesis market report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
| 1.Executive Summary |
| 2.Global Autologous Matrix-induced Chondrogenesis Market Introduction |
| 2.1.Global Autologous Matrix-induced Chondrogenesis Market - Taxonomy |
| 2.2.Global Autologous Matrix-induced Chondrogenesis Market - Definitions |
| 2.2.1. By Material Type |
| 2.2.2. By Application |
| 2.2.3. By End Users |
| 2.2.4. By Region |
| 3.Global Autologous Matrix-induced Chondrogenesis Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Autologous Matrix-induced Chondrogenesis Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Autologous Matrix-induced Chondrogenesis Market By Material Type , 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 5.1. Hyaluronic Acid |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Polyethylene glycol (PEG) |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Collagen |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Polylactic-co-glycolic Acid |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Others |
| 5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6.Global Autologous Matrix-induced Chondrogenesis Market By Application, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 6.1. Knee Cartilage Repair |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Elbow Cartilage Repair |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Hip Cartilage Repair |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Others |
| 6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 7.Global Autologous Matrix-induced Chondrogenesis Market By End Users, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 7.1. Hospitals |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Clinics |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Ambulatory Surgical Centers (ASCs) |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Autologous Matrix-induced Chondrogenesis Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Autologous Matrix-induced Chondrogenesis Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 9.1. Material Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Hyaluronic Acid |
| 9.1.2.Polyethylene glycol (PEG) |
| 9.1.3.Collagen |
| 9.1.4.Polylactic-co-glycolic Acid |
| 9.1.5.Others |
| 9.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Knee Cartilage Repair |
| 9.2.2.Elbow Cartilage Repair |
| 9.2.3.Hip Cartilage Repair |
| 9.2.4.Others |
| 9.3. End Users Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospitals |
| 9.3.2.Clinics |
| 9.3.3.Ambulatory Surgical Centers (ASCs) |
| 9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Autologous Matrix-induced Chondrogenesis Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 10.1. Material Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Hyaluronic Acid |
| 10.1.2.Polyethylene glycol (PEG) |
| 10.1.3.Collagen |
| 10.1.4.Polylactic-co-glycolic Acid |
| 10.1.5.Others |
| 10.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Knee Cartilage Repair |
| 10.2.2.Elbow Cartilage Repair |
| 10.2.3.Hip Cartilage Repair |
| 10.2.4.Others |
| 10.3. End Users Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospitals |
| 10.3.2.Clinics |
| 10.3.3.Ambulatory Surgical Centers (ASCs) |
| 10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) Autologous Matrix-induced Chondrogenesis Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 11.1. Material Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Hyaluronic Acid |
| 11.1.2.Polyethylene glycol (PEG) |
| 11.1.3.Collagen |
| 11.1.4.Polylactic-co-glycolic Acid |
| 11.1.5.Others |
| 11.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Knee Cartilage Repair |
| 11.2.2.Elbow Cartilage Repair |
| 11.2.3.Hip Cartilage Repair |
| 11.2.4.Others |
| 11.3. End Users Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospitals |
| 11.3.2.Clinics |
| 11.3.3.Ambulatory Surgical Centers (ASCs) |
| 11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Autologous Matrix-induced Chondrogenesis Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 12.1. Material Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Hyaluronic Acid |
| 12.1.2.Polyethylene glycol (PEG) |
| 12.1.3.Collagen |
| 12.1.4.Polylactic-co-glycolic Acid |
| 12.1.5.Others |
| 12.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Knee Cartilage Repair |
| 12.2.2.Elbow Cartilage Repair |
| 12.2.3.Hip Cartilage Repair |
| 12.2.4.Others |
| 12.3. End Users Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospitals |
| 12.3.2.Clinics |
| 12.3.3.Ambulatory Surgical Centers (ASCs) |
| 12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Autologous Matrix-induced Chondrogenesis Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 13.1. Material Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Hyaluronic Acid |
| 13.1.2.Polyethylene glycol (PEG) |
| 13.1.3.Collagen |
| 13.1.4.Polylactic-co-glycolic Acid |
| 13.1.5.Others |
| 13.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Knee Cartilage Repair |
| 13.2.2.Elbow Cartilage Repair |
| 13.2.3.Hip Cartilage Repair |
| 13.2.4.Others |
| 13.3. End Users Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospitals |
| 13.3.2.Clinics |
| 13.3.3.Ambulatory Surgical Centers (ASCs) |
| 13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Anika Therapeutics, Inc. (U.S.) |
| 14.2.2.Arthro-Kinetics AG (Germany) |
| 14.2.3.Braun Melsungen AG (Germany) |
| 14.2.4.BioTissue AG (Switzerland) |
| 14.2.5.CartiHeal (Israel) |
| 14.2.6.Geistlich Pharma AG (Switzerland) |
| 14.2.7.JRI Orthopaedics Ltd. (AK Medical) (U.K.) |
| 14.2.8.Matricel GmbH Germany) |
| 14.2.9.Smith & Nephew plc (U.K.) |
| 14.2.10.Zimmer Biomet Holdings (U.S.) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Anika Therapeutics, Inc. (U.S.)
- Arthro-Kinetics AG (Germany)
- Braun Melsungen AG (Germany)
- BioTissue AG (Switzerland)
- CartiHeal (Israel)
- Geistlich Pharma AG (Switzerland)
- JRI Orthopaedics Ltd. (AK Medical) (U.K.)
- Matricel GmbH Germany)
- Smith & Nephew plc (U.K.)
- Zimmer Biomet Holdings (U.S.)